Document:

Exhibit 10.29

 

SPONSOR DESIGNEE RECOMMENDATION AGREEMENT

 

This SPONSOR DESIGNEE RECOMMENDATION AGREEMENT (this “Agreement”), dated as of May 21, is entered into by and between ConforMIS, Inc. (the “Company”) and Procific (the “Sponsor”).

 

RECITALS

 

WHEREAS, the Company is currently contemplating an underwritten public offering (the “IPO”) of shares of Common Stock; and

 

WHEREAS, in connection with, and effective upon, completion of the IPO, the Company and the Sponsor wish to set forth certain understandings between such parties, including with respect to certain matters related to the Board.

 

NOW, THEREFORE, in consideration of the mutual covenants contained herein and for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

ARTICLE I

DEFINITIONS

 

Section 1.1 Certain Definitions. As used in this Agreement, the following terms shall have the following meanings:

 

“2017 Annual Meeting” means the Company’s annual meeting of stockholders held in 2017.

 

“Affiliate” of a specified Person is a Person that directly, or indirectly through one or more intermediaries, Controls, is Controlled by, or is under common Control with, the Person specified.

 

“Agreement” has the meaning set forth in the preamble to this Agreement.

 

“Beneficial Owner” of a security is a Person who directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise has or shares (i) voting power, which includes the power to vote, or to direct the voting of, such security and/or (ii) investment power, which includes the power to dispose, or to direct the disposition of, such security. The terms “Beneficially Own” and “Beneficial Ownership” shall have correlative meanings.

 

“Board” means the Board of Directors of the Company.

 

“Change of Control” means the occurrence of any one of the following: (i) any “person”, as such term is used in Section 13(d) and 14(d) of the Exchange Act (other than the Company, a Subsidiary, an Affiliate, or a Company employee benefit plan, including any trustee of such plan acting as trustee) is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of

 

 

the combined voting power of the Company’s then outstanding securities; or (ii) a sale of assets involving 75% or more of the fair market value of the assets of the Company as determined in good faith by the Board; or (iii) any merger, reorganization or other transaction of the Company whether or not another entity is the survivor, pursuant to which holders of all the shares of capital stock of the Company outstanding prior to the transaction hold, as a group, less than 50% of the shares of capital stock of the Company outstanding after the transaction; provided, however, that neither (A) a merger effected exclusively for the purpose of changing the domicile of the Company in which the holders of all the shares of capital stock of the Company immediately prior to the merger hold the voting power of the surviving entity following the merger in the same relative amounts with substantially the same rights, preferences and privileges, nor (B) a transaction the primary purpose of which is to raise capital for the Company, will constitute a Change of Control.

 

“Common Stock” means the common stock, par value $0.00001 per share, of the Company.

 

“Company” has the meaning set forth in the preamble to this Agreement.

 

“Control” (including the terms “Controlling,” “Controlled by” and “under common Control with”) means the possession, direct or indirect, of the power to (a) direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise or (b) vote 10% or more of the securities having ordinary voting power for the election of directors of a Person.

 

“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

“IPO” has the meaning set forth in the recitals to this Agreement.

 

“Person” means any individual, corporation, firm, partnership, joint venture, limited liability company, estate, trust, business association, organization, any court, administrative agency, regulatory body, commission or other governmental authority, board, bureau or instrumentality, domestic or foreign and any subdivision thereof or other entity, and also includes any managed investment account.

 

“Proceeding” has the meaning set forth in Section 4.6 of this Agreement.

 

“Recommended Individual” has the meaning set forth in Section 2.1 of this Agreement.

 

“Selected Courts” has the meaning set forth in Section 4.6 of this Agreement.

 

“Subsidiary” of any Person means any Person (i) of which a majority of the outstanding voting securities or other voting equity interests are owned, directly or indirectly, by such first Person or any Subsidiary of such first Person or (ii) with respect to which such Person or any of its Subsidiaries is a general partner or managing member or is allocated or has the right to be allocated (through partnership interests or otherwise) a majority of such second Person’s gains or losses.

 

Section 1.2 Rules of Construction. Unless the context otherwise requires:

 

2

 

(a) References in the singular or to “him,” “her,” “it,” “itself” or other like references, and references in the plural or the feminine or masculine reference, as the case may be, shall also, when the context so requires, be deemed to include the plural or singular, or the masculine or feminine reference, as the case may be;

 

(b) References to Articles and Sections shall refer to articles and sections of this Agreement, unless otherwise specified;

 

(c) The headings in this Agreement are for convenience and identification only and are not intended to describe, interpret, define or limit the scope, extent or intent of this Agreement or any provision thereof;

 

(d) This Agreement shall be construed without regard to any presumption or other rule requiring construction against the party that drafted and caused this Agreement to be drafted; and

 

(e) References to “including” in this Agreement shall mean “including, without limitation,” whether or not so specified.

 

ARTICLE II

SPONSOR DESIGNEE RECOMMENDATION

 

Section 2.1 Sponsor Designee Recommendation.

 

(a)                                 Subject to the terms and conditions hereof, in the event that Colm Lanigan should cease to serve as a member of the Board prior to the expiration of his term upon the commencement of the 2017 Annual Meeting, prior to filling such vacancy, the Company will provide the Sponsor with an opportunity to recommend to the Nominating and Corporate Governance Committee of the Board an individual to fill the vacancy created by such cessation and to serve for the balance of Mr. Lanigan’s incompleted term (such recommended individual, the “Recommended Individual”); provided, however, that the Sponsor shall no longer have the rights set forth hereunder at such time as the Sponsor and its Affiliates collectively Beneficially Own less than 5% of the outstanding shares of Common Stock.

 

(b) Each Recommended Individual must satisfy the requirements of applicable law and the independence requirements imposed by the rules of any national securities exchange on which the Common Stock may be listed or traded.

 

ARTICLE III

EFFECTIVENESS AND TERMINATION

 

Section 3.1 Effectiveness. Upon the closing of the IPO, this Agreement shall thereupon be deemed to be effective.

 

Section 3.2 Termination. Unless earlier terminated in accordance with the terms hereof, this Agreement shall terminate upon the earlier to occur of (a) a Change of Control, (b) the delivery of written notice to the Company by the Sponsor requesting the termination of this Agreement, (c) the commencement of the 2017 Annual Meeting and (d) on the date that is three months

 

3

 

following the date of this Agreement in the event that the Company has not consummated the IPO prior to such date.

 

ARTICLE IV

MISCELLANEOUS

 

Section 4.1 Notices. All notices, requests, consents and other communications hereunder to any party shall be in writing and shall be personally delivered, sent by nationally recognized overnight courier or mailed by registered or certified mail to such party at the address set forth below (or such other address as shall be specified by like notice). Notices will be deemed to have been given hereunder when personally delivered, one calendar day after deposit with a nationally recognized overnight courier and five calendar days after deposit in U.S. mail.

 

(a) if to the Company, to:

 

ConforMIS, Inc.

28 Crosby Drive

Bedford, MA 01730

Attention: President

 

(b) if to the Sponsor, to: [             ].

 

Section 4.2 Severability. The provisions of this Agreement shall be deemed severable, and the invalidity or unenforceability of any provision shall not affect the validity or enforceability of the other provisions hereof. If any provision of this Agreement, or the application thereof to any Person or any circumstance, is found to be invalid or unenforceable in any jurisdiction, (a) a suitable and equitable provision shall be substituted therefor in order to carry out, so far as may be valid and enforceable, the intent and purpose of such invalid or unenforceable provision and (b) the remainder of this Agreement and the application of such provision to other Persons or circumstances shall not be affected by such invalidity or unenforceability, nor shall such invalidity or unenforceability affect the validity or enforceability of such provision, or the application thereof, in any other jurisdiction.

 

Section 4.3 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which, taken together, shall be considered one and the same agreement.

 

Section 4.4 Entire Agreement; No Third Party Beneficiaries. This Agreement (a) constitutes the entire agreement and supersedes all other prior agreements, both written and oral, among the parties with respect to the subject matter hereof and (b) is not intended to confer upon any Person, other than the parties hereto, any rights or remedies hereunder.

 

4

 

Section 4.5 Governing Law; Equitable Remedies. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE (WITHOUT GIVING EFFECT TO CONFLICT OF LAWS PRINCIPLES THEREOF). The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with its specific terms or was otherwise breached. It is accordingly agreed that the parties hereto shall be entitled to an injunction or injunctions and other equitable remedies to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any of the Selected Courts, this being in addition to any other remedy to which they are entitled at law or in equity. Any requirements for the securing or posting of any bond with respect to such remedy are hereby waived by each of the parties hereto. Each party further agrees that, in the event of any action for an injunction or other equitable remedy in respect of such breach or enforcement of specific performance, it will not assert the defense that a remedy at law would be adequate.

 

Section 4.6 Consent To Jurisdiction. With respect to any suit, action or proceeding (“Proceeding”) arising out of or relating to this Agreement, each of the parties hereto hereby irrevocably (a) submits to the exclusive jurisdiction of the Court of Chancery of the State of Delaware and the United States District Court for the District of Delaware and the appellate courts therefrom (the “Selected Courts”) and waives any objection to venue being laid in the Selected Courts whether based on the grounds of forum non conveniens or otherwise and hereby agrees not to commence any such Proceeding other than before one of the Selected Courts; provided, however, that a party may commence any Proceeding in a court other than a Selected Court solely for the purpose of enforcing an order or judgment issued by one of the Selected Courts; (b) consents to service of process in any Proceeding by the mailing of copies thereof by registered or certified mail, postage prepaid, or by recognized international express carrier or delivery service, to the Company or the Sponsor at their respective addresses referred to in Section 4.1 hereof; provided, however, that nothing herein shall affect the right of any party hereto to serve process in any other manner permitted by law; and (c) TO THE EXTENT NOT PROHIBITED BY APPLICABLE LAW THAT CANNOT BE WAIVED, WAIVES, AND COVENANTS THAT IT WILL NOT ASSERT (WHETHER AS PLAINTIFF, DEFENDANT OR OTHERWISE) ANY RIGHT TO TRIAL BY JURY IN ANY ACTION ARISING IN WHOLE OR IN PART UNDER OR IN CONNECTION WITH THIS AGREEMENT, WHETHER NOW EXISTING OR HEREAFTER ARISING, AND WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE, AND AGREES THAT EITHER OF THEM MAY FILE A COPY OF THIS PARAGRAPH WITH ANY COURT AS WRITTEN EVIDENCE OF THE KNOWING, VOLUNTARY AND BARGAINED-FOR AGREEMENT AMONG THE PARTIES IRREVOCABLY TO WAIVE THE RIGHT TO TRIAL BY JURY IN ANY PROCEEDING WHATSOEVER BETWEEN THEM RELATING TO THIS AGREEMENT AND TO HAVE ALL MATTERS RELATING TO THIS AGREEMENT BE TRIED IN A COURT OF COMPETENT JURISDICTION BY A JUDGE SITTING WITHOUT A JURY.

 

Section 4.7 Amendments; Waivers.

 

(a) No provision of this Agreement may be amended or waived unless such amendment or waiver is in writing and signed, in the case of an amendment, by each of the parties hereto, or in the case of a waiver, by the party against whom the waiver is to be effective.

 

5

 

(b) No failure or delay by a party in exercising any right, power or privilege hereunder shall operate as waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law.

 

Section 4.8 Assignment. Neither this Agreement nor any of the rights or obligations hereunder shall be assigned by either of the parties hereto without the prior written consent of the other party. Subject to the preceding sentence, this Agreement will be binding upon, inure to the benefit of and be enforceable by the parties and their respective successors and assigns.

 

[Remainder of Page Intentionally Left Blank]

 

6

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed and delivered, all as of the date first set forth above.

 

	
 
    	
CONFORMIS, INC.
    
	
 
    	
 
    
	
 
    	
By:  
    	
/s/   Philipp Lang
    
	
 
    	
Name: Philipp Lang
    
	
 
    	
Title: Chief   Executive Officer
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
PROCIFIC
    
	
 
    	
 
    
	
 
    	
By:  
    	
/s/   Ahmed Abdullatif Ahmed Ibrahim Al Mosa
    
	
 
    	
Name: Ahmed   Abdullatif Ahmed Ibrahim Al Mosa
    
	
 
    	
Title: Authorized   Signatory
    
	
 
    	
 
    
	
 
    	
By:  
    	
/s/   Saeed Musallan Khamis AlMazrovel
    
	
 
    	
Name: Saeed Musallan   Khamis AlMazrovel
    
	
 
    	
Title: Authorized   Signatory
    

 

7Exhibit 10.30

 

	

    
	
July 16, 2013
    

 

	
CONFIDENTIAL
    	
 
    
	
 
    	
Philip Lang, M.D.
    
	
Stanhope   Investments
    	
Chief Executive Officer
    
	
Silver   Tower
    	
28 Crosby Drive
    
	
Corniche   Road
    	
Bedford, MA 01730
    
	
P.O. Box   61999
    	
philipp.lang@conformis.com
    
	
Abu   Dhabi, United Arab Emirates
    	
 
    
	
Attention:   Mark Cutis
    	
 
    
	
Tel:
    	
+971 2 611 5853
    	
 
    
	
Fax:
    	
+971   2 626 6166
    	
 
    
	
Email:   ss@adcouncil.ae
    	
 
    

 

Re:                             Right to Invest in Initial Public Offering

 

Gentlemen:

 

Reference is made to the letter agreement (the “First Letter Agreement”) dated as of January 11, 2012 (the “Effective Date”) by and among ConforMIS, Inc., a Delaware corporation (the “Company”), and Stanhope Investments, a Cayman Islands exempt company (“Stanhope”). The First Letter Agreement may be amended by agreement of the Company and Stanhope.  The Company and Stanhope have agreed to clarify the rights of Stanhope set forth in Section 12 of the First Letter Agreement by superseding and replacing Section 12 of the First Letter Agreement in its entirety with this letter agreement (this “Second Letter Agreement”).  Further, the Company and Stanhope have agreed to supersede and terminate the First Letter Agreement as set forth in the Financing Documents (as such term is defined in the Amended and Restated Information and Registration Rights Agreement dated as of July 16, 2013, by and among the Company and the Investors named therein).  Both parties agree that this Second Letter Agreement is effective as of the Effective Date and is not intended to grant a new right to Stanhope but rather to clarify and modify the existing right previously set forth in Section 12 of the First Letter Agreement.

 

The parties agree as follows:

 

1.                                      The Company agrees that contingent upon Stanhope continuing to hold at least 600,000 shares of the Company’s Series E-1 Preferred Stock and/or Series E-2 Preferred Stock (together, the “Shares”), Stanhope shall have the right but not the obligation to invest an additional USD $25,000,000 in the Company’s “Qualifying IPO” (as defined below) provided such Qualifying IPO is no sooner than one year from the Effective Date.  Stanhope’s right to participate in the Qualifying IPO pursuant to this Second Letter Agreement shall be subject to any carve backs, restrictions and other limitations reasonably requested by the Company’s underwriters in connection with the Qualifying IPO.  Such right shall also be subject to Stanhope’s full compliance with applicable securities laws as directed by the Company and its legal counsel.  “Qualifying IPO” means the closing of the first firm commitment underwritten

 

 

public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of Company Common Stock for the account of the Company to the public with aggregate proceeds to the Company not less than $50,000,000  (before deduction for underwriters commissions and expenses) and a per share price not less than $10.00 per share (appropriately adjusted for combinations consolidations, subdivisions, stock splits or other similar transactions).

 

2.                                      At any time following a determination by the Company’s Board of Directors to initiate a process intended to result in the submission of a registration statement for a Qualifying IPO, but in any event no less than 10 business days prior to the actual submission of such registration statement, the Company will give Stanhope written notice of such submission, which notice will include a good faith estimate by the Company of the approximate timing of such proposed Qualifying IPO, the identity of the lead investment bankers, if any, representing the Company in such Qualifying IPO, a good faith estimate of the approximate price range to be proposed by the Company, and any other material terms then known to the Company relating to the proposed Qualifying IPO.  Stanhope acknowledges that the Company shall not thereafter be obligated to update any information provided in such notice.  Stanhope will have until 10 business days after the Company gives such notice to notify the Company in writing that Stanhope elects to exercise its contractual right to participate in the Qualifying IPO and the amount of its participation (up to USD $25,000,000 but in any event no less than USD $10,000,000).  If Stanhope fails to respond within 10 business days after the Company gives notice, Stanhope will be deemed to have elected not to exercise its contractual right to participate in the Qualifying IPO.  Upon its election to participate in the Qualifying IPO, except in the event of a “Material Adverse Event” (as defined below) with respect to the Company, Stanhope will be firmly bound by such election and will participate in the Qualifying IPO on the same terms as other participants in the Qualifying IPO regardless of, without limitation, any subsequent changes in circumstances of the Company, Stanhope or market conditions, or the ultimate price per share of the Qualifying IPO falling outside the good faith range initially provided to Stanhope.

 

3.                                      Upon the occurrence of a Material Adverse Event after Stanhope’s election to participate in the Qualifying IPO, the Company will provide prompt notice to Stanhope describing the circumstances relating to such Material Adverse Event.  If Stanhope fails to respond within 10 business days after the Company gives such notice, Stanhope will be deemed to have elected not to withdraw the exercise of its contractual right to participate in the Qualifying IPO and shall thereafter continue to be bound as described above.  If Stanhope elects to withdraw the exercise of its contractual right to participate in the Qualifying IPO, Stanhope will no longer have such right and the Company will be under no further obligations to Stanhope pursuant to this Second Letter Agreement; provided, however, that (a) if Stanhope elects to withdraw the exercise of its contractual right to participate in the Qualifying IPO following a Material Adverse Event pursuant to this Section 3, (b) the Company’s Board of Directors then later determines to abandon the process intended to result in the submission of a registration statement for a Qualifying IPO, (c) the Company withdraws or otherwise abandons the registration statement or other filings relating to such process with the SEC, and (d) the Company’s Board of Directors thereafter makes a new determination to initiate a process intended to result in the submission of a registration statement for a Qualifying IPO, Stanhope’s

 

 

rights pursuant to this Second Letter Agreement, including the right to participate in the Qualifying IPO pursuant to Section 2, shall revive.

 

4.                                      For purposes of this Second Letter Agreement, “Material Adverse Event” means the determination by the Company’s Board of Directors that a change, event or effect has occurred that is materially adverse to the general affairs, business, operations, assets, condition (financial or otherwise) or results of operations of the Company; provided, however, that the following shall not be taken into account in determining a “Material Adverse Event”:  (a) any adverse change, event or effect that is directly attributable to conditions affecting the United States or world economies generally unless such conditions adversely affect the Company in a materially disproportionate manner, and (b) any adverse change, event or effect that is directly attributable to conditions affecting the Company’s industry generally, unless such conditions adversely affect the Company in a materially disproportionate manner.  No change, event or effect shall be considered to be a Material Adverse Event unless, at a minimum, the Company’s Board of Directors determines that such change, event or effect has or is likely to cause a diminution in value of the Company of at least 25%.  Without limiting the foregoing, in no event shall price adjustments preceding an initial public offering constitute a Material Adverse Event, nor shall litigation initiated by or against the Company until a final judgment is entered.

 

5.                                      This Second Letter Agreement will not be affected by the termination of the First Letter Agreement.  This Second Letter Agreement and the rights described herein shall terminate and be of no further force or effect upon the earliest of (i) Stanhope’s election not to participate in a Qualifying IPO after having been notified of such Qualifying IPO in accordance with this Second Letter Agreement (or after having been notified of a Material Adverse Event), (ii) Stanhope’s participation in a Qualifying IPO pursuant to this Second Letter Agreement, (iii) Stanhope no longer holding at least 600,000 Shares, or (iv) a “Change of Control” (as defined below).

 

6.                                      This Second Letter Agreement shall be governed by and construed according to the laws of the State of New York, excluding those laws that direct the application of the laws of another jurisdiction.  In the event that any legal action becomes necessary to enforce or interpret the terms of this Second Letter Agreement, the parties hereto agree that such action will be brought in the state or federal courts located in Middlesex County or Suffolk County in the Commonwealth of Massachusetts, and such parties hereby submit to the jurisdiction and venue of such courts.  The Company understands and agrees that its failure to comply with the obligations under this Second Letter Agreement will cause Stanhope to suffer irreparable injury and harm, the full extent of which will, or may, be impossible to ascertain, and for which monetary damages will not be a complete remedy.  Accordingly, the Company agrees that Stanhope will, in addition to any other remedies available to it at law or in equity, be entitled to preliminary and permanent injunctive relief to enforce, or to prevent a breach of, the terms of this Second Letter Agreement.

 

7.                                      This Second Letter Agreement contains the parties’ complete understandings and agreements regarding the matters set forth herein.  Other than the First Letter Agreement, there are no other, different or prior agreements or understandings on this or related subjects.  This Second Letter Agreement is effective notwithstanding Section 6.12 of the Purchase Agreements

 

 

and provisions of the First Letter Agreement that provide that the First Letter Agreement contains the parties’ complete understandings and agreements regarding the matters set forth therein.  The rights and obligations under this Second Letter Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties, including without limitation any “Affiliates” (as defined below) of Stanhope, provided that (i) Stanhope may at any time and without consent of the Company (but in accordance with applicable securities laws and with notice to the Company) assign and/or novate to an Affiliate of Stanhope all or any portion of its Shares and all associated rights and obligations (including, without limitation, under this Second Letter Agreement) but otherwise may not assign its rights and obligations hereunder without prior written notice to and consent of the Company and (ii) the Company may not assign its rights and obligations hereunder without the prior written consent of Stanhope except in connection with a Change in Control.  For purposes of this Second Letter Agreement, “Affiliates” shall mean any member of Stanhope’s board of directors, any executive officer of Stanhope, any holder of at least 10% of the outstanding capital stock of Stanhope or any entity controlled, directly or indirectly, by Stanhope, any entity that controls, directly or indirectly, Stanhope or any entity directly or indirectly under common control with Stanhope. For purposes of this Second Letter Agreement, a “Change in Control” shall mean the sale, lease, assignment, transfer, conveyance or disposal of all or substantially all of the assets of the Company, or the acquisition of the Company by another entity by means of consolidation, corporate reorganizations or merger, or other transaction or series of related transactions in which more than 50% of the outstanding voting power of this Company is disposed of other than any transaction primarily for financing purposes.

 

8.                                      Any notice required or permitted hereunder shall be given in writing and shall be conclusively deemed effectively given upon personal delivery or delivery by courier, or on the first business day after transmission if sent by confirmed facsimile transmission or electronic mail transmission, or 15 business days after deposit in the United States mail, by registered or certified mail, postage prepaid, addressed (i) if to the Company, at 28 Crosby Drive, Bedford, MA 01730 or [Fax Number], and (ii) if to Stanhope, at Stanhope’s contact information set forth above, or at such other address, facsimile number or email address as the Company or Stanhope may designate by 10 business days’ advance written notice to the other party hereto.

 

9.                                      This Second Letter Agreement will not be affected by the termination of the First Letter Agreement.  This Second Letter Agreement may not be amended except by a written agreement signed by authorized representatives of each party.  This Second Letter Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  This Second Letter Agreement may be executed by facsimile signature (including signatures in Adobe PDF or similar format).

 

[Remainder of Page Intentionally Left Blank]

 

 

If you are in agreement with the terms set forth above, please sign this Second Letter Agreement in the space provided below.

 

	
 
    	
Very   truly yours,
    
	
 
    	
 
    
	
 
    	
CONFORMIS, INC.
    
	
 
    	
 
    
	
 
    	
/s/ Philipp Lang
    
	
 
    	
 
    
	
 
    	
Philipp   Lang, M.D.
    
	
 
    	
Chief   Executive Officer
    
	
 
    	
 
    
	
Agreed   by:
    	
 
    
	
 
    	
 
    
	
STANHOPE INVESTMENTS
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
/s/ Salem Mohamed Al Ameri   /s/   Mark Cutis
    	
 
    
	
[SIGNATURE]
    	
 
    
	
 
    	
 
    
	
Salem Mohamed Al Ameri & Mark Cutis
    	
 
    
	
[NAME]
    	
 
    
	
 
    	
 
    
	
Director & Business Officer
    	
 
    
	
[TITLE]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00245-of-00352.parquet"}]]